Radiopharm Theranostics (ASX:RAD) presents RAD 202 data at 2024 EANM annual meeting

1 min read | October 22, 2024 09:21 PM EDT | By Sonal Goyal

Google News:

Radiopharm Theranostics (ASX:RAD) presents RAD 202 data at 2024 EANM annual meeting — Image source: Company update

Recent News

Three Penny Stocks Benefiting From Growing Gold Exposure

Energy Fuels Growth Narrative Expands As Rare Earth Demand Rises

Advantage Energy Leadership Shift Sparks Fresh Market Attention

Why Ero Copper (TSX:ERO) Is Drawing Attention After Furnas Progress?

Make Kalkine Media
My Trusted Source

Highlights

Radiopharm Theranostics presented new imaging data for Ga68-RAD 202 at the 2024 EANM Annual Meeting.

PET/CT data in HER2-positive murine models show minimal nonspecific organ uptake of 68Ga-RAD 202, except in bladder and kidneys.

RAD 202 demonstrates rapid tumor uptake and a high tumor-to-background ratio, independent of the His-tag modification.

A First-In-Human (FIH) Phase 1 dose-escalation study of 177Lu-RAD 202 will begin in Q4 2024 in Australia.

Radiopharm Theranostics Limited (ASX:RAD) announces poster presentation of new imaging data for Ga68-RAD 202 at 2024 European Association of Nuclear Medicine (EANM) Annual Meeting. Drs. Felix Mottaghy, Betul Altunay and colleagues, from the University Hospital RWTH Aachen in Germany, presented the data at EANM 2024.

RAD shares were trading 1.79% higher at AU$0.028 apiece at the time of drafting on 23 October 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.